Ipodate sodium

Ipodate sodium
Clinical data
Trade names	Oragrafin
Routes of; administration	oral, Intravenous
ATC code	V08AC08 (WHO) ;
Identifiers
	IUPAC name sodium 3-(3-{[(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoate;
CAS Number	5587-89-3;
PubChem CID	14651;
ChemSpider	13984;
UNII	F604ZKI910;
ChEMBL	ChEMBL1201033;
CompTox Dashboard (EPA)	DTXSID9048271 ;
ECHA InfoCard	100.013.587
Chemical and physical data
Formula	C12H12I3N2NaO2
Molar mass	619.943 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	168–169 °C (334–336 °F)
	SMILES CN(C)/C=N/c1c(cc(c(c1I)CCC(=O)[O-])I)I.[Na+];
	InChI InChI=1S/C12H13I3N2O2.Na/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19;/h5-6H,3-4H2,1-2H3,(H,18,19);/q;+1/p-1/b16-6+;; Key:ZFHZUGUCWJVEQC-FPUQOWELSA-M;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Ipodate sodium (sodium iopodate) is an iodine-containing radiopaque contrast media used for X-rays. The drug is given orally and the resulting contrast allows for easy resolution of the bile duct and gall bladder.

Other uses

Although not FDA approved, ipodate sodium has been used to treat Graves' disease and thyroid storm, an extreme form of hyperthyroidism.

Graves' disease

Long-term treatment of Graves' disease with ipodate sodium (500 mg, daily) given by mouth reduced levels of T3 and T4 in the patients.^[1] This was done with minimal side effects, indicating possible clinical usefulness. Iodine uptake was also noted to return to normal within seven days, indicating control with ipodate with rapid follow up treatment with ¹³¹I is feasible.

Thyroid storm

In emergency situations, ipodate can be administered for thyroid storm. As the ipodate is metabolized, it releases iodine into circulation, helping bring the T3 and T4 levels back down. Ipodate also inhibits the conversion of T4 to T3 (which is more potent). It is not considered a first-line approach, as potassium iodide and beta blockers have less potential for side-effects. Ipodate sodium lacks FDA approval for this use.

References

^ Shen DC, Wu SY, Chopra IJ, Huang HW, Shian LR, Bian TY, et al. (October 1985). "Long term treatment of Graves' hyperthyroidism with sodium ipodate". The Journal of Clinical Endocrinology and Metabolism. 61 (4): 723–7. doi:10.1210/jcem-61-4-723. PMID 3928675. Archived from the original on 2008-07-25. Retrieved 2008-04-14.

[1] Shen DC, Wu SY, Chopra IJ, Huang HW, Shian LR, Bian TY, et al. (October 1985). "Long term treatment of Graves' hyperthyroidism with sodium ipodate". The Journal of Clinical Endocrinology and Metabolism. 61 (4): 723–7. doi:10.1210/jcem-61-4-723. PMID 3928675. Archived from the original on 2008-07-25. Retrieved 2008-04-14.

[1]